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Purpose: transcatheter aortic valve implantation (TAVI), performed either
by transfemoral (TF) or transapical (TA) approach, is an emerging technique
for the treatment of severe aortic stenosis (AS) in high-risk patients. It is
unclear whether TF- or TA-TAVI compares favourably with modern conven-
tional surgical aortic valve replacement (SAVR) in a high-risk population.
Methods: we conducted a two-centre observational prospective cohort
study. High-risk patients (Logistic EuroScore  15 % and/or STS Score > 10 %)
with symptomatic severe AS were treated either by SAVR or by TAVI. TF
approach was the first choice for TAVI, using both the balloon-expandable or
the self-expandable available bioprostheses. TA approach was used when TF
approach was contra-indicated. Baseline characteristics, 30-day functional
status, prostheses mean gradient (MG) (efficacy endpoint), and 30-day all-
cause mortality (safety endpoint) were compared.
Results: 143 patients were included: 58 underwent SAVR, 60 underwent
TF-TAVI and 25 TA-TAVI. Mean age, aortic valve area and left ventricular
ejection fraction were the same in the 3 groups. Patients undergoing TF- and
TA-TAVI had higher Logistic EuroScore (24.0% [20.0-29.0], 25.2% [20.0-
29.8] vs 18.6% [15.8-23.8] respectively, p=0.001) and worse functional status
(NYHA class > or = III: 98 %, 100 % vs 50 % respectively, p<0.0001) than
those treated by SAVR. 30-day functional status and final prostheses MG were
the same in all groups. 30-day all-cause mortality was 17 % in the SAVR
group, 5 % in the TF-TAVI group, and 16 % in the TA-TAVI group (TF-
TAVI vs SAVR: p= 0.05, TA-TAVI vs SAVR: p= 0.999).
Conclusions: These observational data suggest that, in this high-risk pop-
ulation, SAVR and TAVI 30-day effectiveness are equivalent. Only TF-TAVI,
whereas no TA-TAVI when reserved to contraindications of TF approach,
seems to improve the 30-day mortality in comparison with SAVR. 
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Aim: Thanks to improved technology and the advent of transcatheter aortic
valve implantation (TAVI), balloon aortic valvuloplasty (BAV) has reappared
in the management of high risk patients with severe aortic stenosis in a critical
clinical state in three different therapeutic strategies: 1) palliative care [A] 2)
bridge to surgery [B] 3) bridge to TAVI [C]. Our main objective was to assess
the safety, the effiency and the pertinence of BAV.
Methods: Thirty six patients with severe aortic stenosis and prohibitive
surgical risk (logistic Euroscore >15% or severe commorbidities) underwent
39 BAV: 8 in strategy A, 20 in strategy B, 11 in strategy C. 3 patients under-
went a second BAV due to early restenosis.
Results: There was a significant improvement of the hemodynamic param-
eters after BAV: the peak to peak transaortic gradient was reduced by 56%
(47mmHg vs 30mmHg; p<0.001) and index valve area was increased by 48%
(0.35 vs 0.52 cm2/m2; p < 0.001). There was no severe procedural complica-
tion (no death due to procedure, no massive aortic insuffisiency, no tam-
ponade). Two patients (5.1%) needed a pacemaker implantation for
postprocedure atrioventricular block and 6 patients (15.4%) had moderate
bleeding of the femoral artery site. The mortality and follow up for the three
strategies are summarized in the table.
Conclusion: BAV is a safe and efficient transient therapeutic strategy for
patients with severe aortic stenosis with prohibitive surgical risk. BAV appears
to be more pertinent in bridge to surgery or brige to TAVI than in palliative
care. For patients in critical clinical state, BAV stabilizes the hemodynamic
status and allows the assessment of anatomical selection criteria for TAVI
 Stratégy A
(n=8)
Stratégy B 
(n=20)
Stratégy C 
(n=11)
Age (mean, min-max) 80 (61-94) 73 (44-85) 81 (60-87)
Mean logistic Euroscore 
(%)
48 22.6 44.2
Death  n (%) 6 (75) 8 (40) 5 (45)
Cardiovascular death 
n (%)
4 (50) 3 (15) 2 (18)
Time of occurrence 
(days, min-max)
12 (0-47) 66 (0-130) 155 (10-316)
Aortic valve replacement 
n (%)
- 14 (70) -
TAVI n (%) - - 2 (18)
